Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q3 2016 call → NOThe question asks whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket, with three conditions: 1. The company is paying now for something not yet earning. 2. Management speaks as though the wait is the company's main current work. 3. The far side is a specific, near-dated, already-visible event. Let me examine the transcript for evidence of this. The company is Supernus Pharmaceuticals, with products Trokendi XR and Oxtellar XR, and pipeline drugs SPN-810 and SPN-812. Key elements in the transcript: - The company has commercial products already earning (Trokendi XR, Oxtellar XR) with strong sales growth. - Pipeline: SPN-810 (Phase 3 trials for impulsive aggression in ADHD) - enrollment continuing, expected to continue into 2017, data likely 2018. - SPN-812 (Phase 2b completed with positive results) - planning end of Phase 2 meeting with FDA, then Phase 3. - The migraine indication for Trokendi XR - FDA granted tentative approval, preparing to launch after full approval. Now, is there a "defined waiting period" the company is paying for out of its own pocket? The SPN-810 trials are being funded, with enrollment slower than expected. R&D expenses are being incurred. But the end is not near-dated - data likely 2018, enrollment through 2017. That's more than a year away. The migraine indication launch - they're preparing to launch after full FDA approval. But the approval hasn't come yet - it's tentative. The launch depends on FDA approval, which is not yet granted. That's a "decision not yet made" - the FDA hasn't given full approval. The restatement issue - that's an accounting matter, not a waiting period. The company's main business is already earning - Trokendi XR and Oxtellar XR are generating significant revenue. The R&D spending on pipeline is normal investment in growth, not a "gap" the company is standing in. Is there any specific near-dated event within a year that management is working toward? The migraine launch - but it depends on FDA approval, which is not yet granted. The SPN-812 Phase 3 initiation - but that's a trial start, not a revenue event. The essence of the question: is the company bearing the cost of a gap it has chosen to stand in, with the far edge already dated and already largely paid for? The company's commercial products are already earning.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.